Document is current
Any future updates will be listed below
-
Authors
England, Ross N.
Drapeau, Elizabeth M.
Alameh, Mohamad-Gabriel https://orcid.org/0000-0002-5672-6930
Hosseinzadeh, Reihaneh
Weissman, Drew
Hensley, Scott E. https://orcid.org/0000-0002-2928-7506
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (75N93021C00015)
- License Information
-
More Information
Article History
Received: 12 April 2023
Accepted: 6 June 2024
First Online: 18 June 2024
Competing interests
: S.E.H. and D.W. are co-inventors on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and as a vaccine platform. R.H. is an employee of Acuitas Therapeutics, a company focused on the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic applications. The authors declare no other competing interests.
